The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.
4Q Earnings: $410 million (loss of $3.4 billion 4Q24) ...
Pfizer posted Q4 revenue of $17.76 billion, up 22% YoY, with strong sales from Paxlovid, Vyndaqel, and Eliquis. The company reaffirmed its 2025 revenue outlook.
Hosted on MSN4d
Pfizer (NYSE:PFE) Posts Better-Than-Expected Sales In Q4Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results , with sales up 21.9% year on year to $17.76 ...
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European ...
Pharmaceutical Technology on MSN12d
Pfizer settles Biohaven kickback claims case for $59.7mBiohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for ...
The global Biosimilar Pipeline Analysis market is expected to grow at 17.8% CAGR from 2025 to 2032. Latest Research Report on the Biosimilar Pipeline Analysis Market Size, Status, and Forecast for ...
US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback